ID: MRFR/Pharma/4475-HCR | | Region: Global | 100 pages
In simple terms, constipation can be defined as the reduced stool frequency which could be less than three times per week. It can also be said to have difficulty passing stool. Chronic idiopathic constipation is a health condition in which the patient suffers from chronic symptoms of constipation. Moreover, constipation is one of the most frequently occurring Gastrointestinal (GI) complaints or problem.
According to a report by the World Gastroenterology Organization, 35 to 40 % of the world’s total population is suffering from acute or chronic GI complication. The increasing number of patients having GI diseases and disorders due to change in dietary pattern is the major factor for driving the global chronic idiopathic constipation market. According to reports from, Allergan and Ironwood Pharmaceuticals, Inc. major symptoms of constipation are infrequent stools (having a bowel movement less than three times a week), difficulty passing stools, which includes straining to have a bowel movement, not completely emptying bowels after a movement, hard or lumpy stools, gas pain, abdominal discomfort, and others.
On the other hand, low awareness regarding diagnosis and treatment methods for chronic idiopathic constipation may hamper the market growth during the forecast period.
Global Chronic Idiopathic Constipation market is expected to grow at a CAGR of 7.4% during the forecast period.
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, Population Reference Bureau, World Cancer Research Fund International, Economic and Social Commission for Asia and the Pacific (ESCAP), World Gastroenterology Organization, Ministry of Health, The American Autoimmune Related Diseases Association, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
The global chronic idiopathic constipation market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the market is segmented into blood tests, sigmoidoscopy, colonoscopy, balloon expulsion test, anorectal manometry, colonic transit study, defecography, and others.
On the basis of treatment, the market is segmented into drug and surgery. Drugs are further segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics, antiulcer, lubiprostone (amitiza) and linaclotide (linzess), misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) and Onabotulinumtoxin A (also called botulinum toxin type A or Botox), and others.
On the basis of end-user, the market is segmented into hospitals, gastroenterology clinics, diagnostic centers and others.
FIGURE 1: Global Chronic Idiopathic Constipation Market, by Region, 2016 (%)
Source: Centers for Disease Control and Prevention, World Health Organization, population reference bureau, Statistics Canada, StatsCan, Centers for Medicare & Medicaid Services, U.S. Census Bureau, Organization for Economic Co-operation and Development, Expert Interview, Market Research Future Analysis, Annual report, White paper, Company Presentation
Regional Analysis of the Global Chronic Idiopathic Constipation Market
The American chronic idiopathic constipation market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven due to the increasing prevalence of chronic constipation and growing investment in healthcare. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing medications for constipation. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic and treatment methods. South America is expected to be the fastest growing market due to technological advancements for diagnosis and increasing demand for treatment options of GI diseases.
The European chronic idiopathic constipation market exhibits growth with an increasing emphasis on the diagnosis and treatment of GI diseases and others. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of GI diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among adults, and addiction to smoking.
On the other hand, the Middle East and Africa holds the least share of the market owing to the less availability of funds, limited availability of medical facilities, and poor political conditions in Africa. The Middle Eastern region holds the major share of the market owing to a well-developed technology and high healthcare expenditure. On the other hand, the African region shows the fastest growth due to the availability of opportunities for the market growth.
Key Players in the Global Chronic Idiopathic Constipation Market
Some of the key players in this market are Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.) and others.
Frequently Asked Questions (FAQ) :
Global chronic idiopathic constipation market is expected to expand at 7.4% CAGR from 2020 to 2027.
Early detection of GI diseases at a preventive stage is the primary driver of the global chronic idiopathic constipation market.
Low awareness of the treatment is the major factor expected to impede the global chronic idiopathic constipation market growth.
The Americas is expected to dominate the global chronic idiopathic constipation market till 2027 due to large number of cases of chronic constipation.
Pfizer Inc, Salix Pharmaceuticals Ltd, Bayer, Sucampo Pharmaceuticals Inc, GlaxoSmithKline, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Synergy Pharmaceuticals, Boehringer Ingelheim GmbH, Progenics Pharmaceuticals, F. Hoffmann-La Roche AG, Daewoong Co. Ltd., Actavis, Synergy Pharmaceuticals, Inc., Ferring International Center S., and Sanofi are prominent players of the global chronic idiopathic constipation market.